Jeffery S. Loutit

The Agent of Bacillary Angiomatosis

David A. Relman, Jeffery S. Loutit, Thomas M. Schmidt et al. · New England Journal of Medicine · 1990 · 898 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Richard G. Wunderink, Evangelos J. Giamarellos‐Bourboulis, Galia Rahav et al. · Infectious Diseases and Therapy · 2018 · 442 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis et al. · JAMA · 2018 · 306 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with <i>Pseudomonas aeruginosa</i>

David E. Geller, Patrick A. Flume, Doris Staab et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 133 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

David C. Griffith, Jeffery S. Loutit, Elizabeth E. Morgan et al. · Antimicrobial Agents and Chemotherapy · 2016 · 79 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12